Comparing Vericel (NASDAQ:VCEL) & Black Diamond Therapeutics (NASDAQ:BDTX)

Black Diamond Therapeutics (NASDAQ:BDTX) and Vericel (NASDAQ:VCEL) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, valuation, analyst recommendations, earnings, institutional ownership and profitability.

Risk and Volatility

Black Diamond Therapeutics has a beta of 3.48, suggesting that its stock price is 248% more volatile than the S&P 500. Comparatively, Vericel has a beta of 1.08, suggesting that its stock price is 8% more volatile than the S&P 500.

Insider and Institutional Ownership

95.5% of Black Diamond Therapeutics shares are held by institutional investors. 9.3% of Black Diamond Therapeutics shares are held by insiders. Comparatively, 7.6% of Vericel shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and recommmendations for Black Diamond Therapeutics and Vericel, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Black Diamond Therapeutics	1	2	7	0	2.60
Vericel	0	2	5	0	2.71

Black Diamond Therapeutics presently has a consensus price target of $11.00, suggesting a potential upside of 585.36%. Vericel has a consensus price target of $62.00, suggesting a potential upside of 4.07%. Given Black Diamond Therapeutics’ higher possible upside, equities research analysts plainly believe Black Diamond Therapeutics is more favorable than Vericel.

Profitability

This table compares Black Diamond Therapeutics and Vericel’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Black Diamond Therapeutics	N/A	-32.10%	-25.21%
Vericel	7.91%	6.91%	5.02%

Earnings & Valuation

This table compares Black Diamond Therapeutics and Vericel”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Black Diamond Therapeutics	$70.00 million	1.32	$22.37 million	($0.75)	-2.14
Vericel	$276.26 million	11.04	$16.52 million	$0.64	93.09

Black Diamond Therapeutics has higher earnings, but lower revenue than Vericel. Black Diamond Therapeutics is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Summary

Vericel beats Black Diamond Therapeutics on 8 of the 14 factors compared between the two stocks.

About Black Diamond Therapeutics

Black Diamond Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetically defined cancers. The company uses its proprietary MasterKey platform to identify and develop small-molecule therapies designed to address oncogenic mutations across multiple tumor types, including alterations that may be difficult to target with conventional approaches. Black Diamond’s pipeline has included brain-penetrant therapies for cancers affecting the central nervous system.

About Vericel

Vericel Corporation is a biopharmaceutical company focused on developing and commercializing cell therapies and other treatments for serious conditions. Based in Cambridge, Massachusetts, the company markets its products primarily in the United States. Its products include MACI, an implant made from a patient’s own cultured cartilage cells used to repair certain cartilage defects in the knee, and Epicel, a cultured skin graft used to treat patients with deep burns. Vericel also commercializes NexoBrid in the United States, an enzyme-based treatment for removing dead tissue from severe thermal burns.